|
Market Closed -
Nasdaq
16:00:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 207.77 USD | -0.12% |
|
-2.76% | +13.76% |
| 08-12 | UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating | MT |
| 08-12 | Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AXSOME THERAPEUTICS, INC. | Biopharmaceuticals | -0.12% | -2.76% | +13.76% | +75.32% | +738.12% | 10.88B |  |  | |
- Stock Market
- Stocks
- AXSM Stock
- Charts Axsome Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
